Infusional chemotherapy for non-Hodgkin's lymphoma

Cancer Investigation

Volumn 15, Issue 5, 1997, Pages 465-474

  Molldrem, Jeff ^a   Wilson, Wyndham H ^a,b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; PACLITAXEL; VINCRISTINE;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG HALF LIFE; DRUG INFUSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LUNG TOXICITY; LYMPHOMA; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0030765129     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909709047586     Document Type: Review

References (65)

1. Lai GM, Chen YN, Mickley LA, et al: P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Intl J Cancer 49:697-703, 1991.
2. Young RC, Schein PS: Enhanced antitumor effect of cytosine arabinoside given in a schedule dictated by kinetic studies in vivo. Biochem Pharmacol 22:277-280, 1973.
3. Lopes NM, Adams EG, Pitts TW, et al: Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32:235-242, 1993. Wilson, et al.
4. Sachs L, Lotem J: Control of programmed cell death in norml and leukemic cells: New implications for therapy. Blood 82:15-21, 1993.
5. Kohn KW, Jackman J, O'Connor PM: Cell cycle control and cancer chemotherapy. J Cell Biochem 54:440-452, 1994.
6. Prokocimer M, Rotter V: Structure and function of p53 in normal cells and their aberrations in cancer cells: Projection on the hematologic cell lineages. Blood 84:2391-2411, 1994.
7. Piris MA, Pezella F, Martinez-Montero JC, et al: p53 and bcl-2 expression in high-grade B-cell lymphomas: Correlation with survival time. Br J Cancer 69:337-341, 1994.
8. Wilson WH, Teruya-Feldstein J, Harris J, et al: p53 but not bcl-2 overexpression is independently associated with drug resistance in relapsed non-Hodgkin's lymphomas treated with EPOCH chemotherapy. Proc Am Soc Clin Oncol 14:1225, 1995 (abstract).
9. Harris CC, Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329:1318-1327, 1993.
10. Hryniuk W, Busch H: The importance of dose intensity in chemotherapy of Melastatic breast cancer. J Clin Oncol 2:1281-1288, 1994.
11. Hryniuk W, Levine MN: Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4:1162-1170, 1986.
12. Goldstein L, Galaski H, Fojo A, et al: Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81:116-120, 1989.
13. Miller T, Grogan T, Dalton W, et al: P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9:17-24, 1991.
14. Wilson WH, Bates SE, Fojo A, et al: Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 13:1995-2004, 1995.
15. Pastan I, Gottesmann M: Multiple-drug resistance in human cancer. N Engl J Med 316:1388-1993, 1987.
16. Chabner BA, Bases SE, Fojo AT, et al: Drug resistance in adult lymphomas. Semin Heme 31:70-87, 1994.
17. Umezawa H, Meada K, Takeuchi T, et al: New antibiotics: Bleomycin A and B. J Antibiot (Tokyo) 19:200-206, 1966.
18. Hall SW, Strong JE, Braughton A: Bleomycin clinical pharmacology by radioimmunoassay. Cancer Chemother Pharmacol 9:22-25, 1982.
19. Broughton A, Strong JE, Hobye PY, et al: Clinical pharmacology of bleomycin following intravenous infusion as determined by radioimmunoassay. Cancer 40:2772-2778, 1977.
20. Parvinen LM, Kilkku P, Maekinen E, et al: Factors affecting the pulmonary toxicity of bleomycin. Acta Radiol 22:417-422, 1983.
21. Drewinko B, Novak JN, Barranco SC: The response of human lymphoma cells in vitro to bleomycin and 1,3-bis(2chloroethyl)-1-nitrosourea. Cancer Res 32:1206-1208, 1972.
22. Ludwig R, Alberts DS, Miller TP, et al: Evaluation of anti-cancer drug schedule dependency using an in vitro human tumor clonogenic assay. Cancer Chemother Pharmacol 12:135-142, 1984.
23. Matsushima Y, Kanzawa F, Hoshi A, et al: Time schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay. Cancer Chemother Pharmacol 14:104-107, 1985.
24. Sikic BI, Collins JM, Mimnaugh EG, et al: Improved therapeutic index of bleomycin when administered by continuous infusion in mice. Cancer Treat Rep 62:2011-2017, 1978.
25. Cooper KR, Hong WK: Prospective study of the pulmonary toxicity of continuously infused bleomycin. Cancer Treat Rep 65:419-425, 1981.
26. Owellen RJ, Hartke CA, Dickerson RM, et al: Inhibition of tubulin-microtubule polymerization by drugs of the vinca alkaloid class. Cancer Res 36:1499-1502, 1976.
27. 3H]vindesine in rats. Cancer Res 37:3053-3056, 1977.
28. Jackson DV, Paschold CH, Spur CL, et al: Treatment of advanced non-Hodgkin's lymphoma with vincristine infusion. Cancer 53:2601-2606, 1984.
29. Ghen GL, Yang L, Rowe TC, et al: Nonintercalative antitumor drugs interfere with the breakage-reunion faction of mammalian DNA topoisomerase II. J Biol Chem 259:13560-13566, 1984.
30. Minocha A, Long BH: Inhibition of the DNA catenation activity of type II topoisomerase by VP16-213 and VM-26. Biochem Biophys Res Commun 122:165-170, 1984.
31. Ratain MJ, Kaminer LS, Bitran JD, et al: Acute non-lymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advance non-small-cell carcinoma of the lung. Blood 70:1412-1418, 1987.
32. Drewinko B, Barlogie B: Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213. Cancer Treat Rep 60:1295-1306, 1978.
33. Venditti JM: Treatment schedule dependency of experimentally active antileukemic (L1210) drugs. Cancer Chemother Rep 2:35-59, 1971.
34. Vietti TJ, Valeriote FA, Kalish R, et al: Kinetics of cytotoxicity of VM-26 and VP-16-213 on L1210 leukemia and hemaiopoietic stem cells. Cancer Treat Rep 62:1313-1320, 1978.
35. Slevin ML, Clark PI, Joel SP, et al: A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7:1333-1340, 1989.
36. Chan KK, Chleboski RT, Myron-Tonn HS, et al: Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis. Cancer Res 40:1263-1269, 1980.
37. Legha SS, Benjamin RS, Mackay B, et al: Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer. Cancer 49:1762-1766, 1982.
38. Hortobagyi GN, Frye D, Buzdar AU, et al: Decreased cardiac toxicity of doxorubicin administration by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 63:37-45, 1989.
39. Legha SS, Benjamin RS, Mackay B, et al: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96:133-139, 1981
40. Plunkett W, Liliemark JO, Estey E, et al: Saturatic of ara-CTP accumulation during high-dose ara-C therapy: Pharmacologic rationale for intermediate-dose Ara-C. Semin Oncol 14(2) Suppl 1:159-166, 1989.
41. Chabner, BA: Cytosine arabinoside. In: Pharmacologic Principles of Cancer Treatment, edited by BA Chabner, Philadelphia, WB Saunders, 1982, pp 387-401.
42. Drewinko B, Ho DHW, Barranco SC: The effects of arabinosylcytosine on cultured human lymphoma cells. Cancer Res 42:1587-1594, 1972.
43. Velasquez WS, McLaughlin P, Tucker S, et al: ESHAP - An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study. J Clin Oncol 12:1169-1176, 1994.
44. Valasquez W, Cabanillas F, Salvador P, et al: Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 71:117-122, 1988.
45. Chabner BA, Young RC: Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Invest 52:1804-1811, 1973.
46. Eichholtz H, Trott KR: Effect of methotrexate concentration and exposure time on mammalian cell survival in vitro. Br J Cancer 41:227-284, 1985.
47. Taylor SG, McGuire WP, Hauck WW, et al: A randomized comparison of high-dose infusion methotrexate versus standard-dose weekly therapy in head and neck squamous cancer. J Clin Oncol 2:1006-1011, 1984.
48. Vogler W, Jacobs J, Moffitt S, et al: Methotrexate therapy with or without citrovorum factor in carcinoma of the head and neck, breast and colon. Cancer Clin Trials 2:227-236, 1979.
49. Druckrey H: Theoretical use of chemotherapy in the treatment of carcinoma. J Kansar (Ankara) 1:130-149, 1970.
50. Goldin A, Venditti JM, Kline, I: Preclinical investigations with ifosphamide in relation to cyctophosphamide. In: Proceedings of the International Holoxan Symposium, edited by H Burkert, HC Voight, Dusseldorf, Germany, 1977, pp 19-28.
51. Hollister D, Silver RT, Gordon B, et al: Continuous infusion vincristine and bleomycin with high dose methotrexate for resistant non-Hodgkin's lymphoma. Cancer 50:1690-1694, 1982.
52. Ginsberg SJ, Cooke ST, Bloomfield CO, et al: Cyclophosphamide, doxorubicin, vincristine, and low-dose continuous infusion bleomycin in non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study #7804. Cancer 49:1346-1352, 1982.
53. Boyd DB, Coleman M, Papish SW, et al: COPBLAM IIP: Infusional combination chemotherapy for diffuse large cell lymphoma. J Clin Oncol 6:425-433, 1988.
54. Coleman M, Armitage JO, Gaynor M, et al: The COP-BLAM programs: Evolving chemotherapy concepts in large cell lymphoma. Semin Hematol 25(2) (Suppl 2):22-33, 1988.
55. Yi PI, Coleman M, Saltz L, et al: Chemotherapy for large cell lymphoma. Semin Oncol 17:60-73, 1990.
56. Armitage JO, Fyfe MA, Lewis J: Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphomas with the CHOP regimen. J Clin Oncol 2:898-902, 1984.
57. Klimo P, Connors JM: MACOP-B Chemotherapy for the treatment of diffuse large cell lymphoma. Ann Intern Med 102:596-602, 1985.
58. Longo DL, DeVita VT, Duffey PL, et al: Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: Results of a prospective randomized trial. J Clin Oncol 9:25-38, 1991.
59. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993.
60. Wilson WH, Bryant G, Bates S, et al: EPOCH chemotherapy toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 11:1573-1582, 1993.
61. Carrion JR, Arroyo G, Salinas P: Infusional chemotherapy (EPOCH) in patients with refractory or relapsed lymphoma. Am J Clin Oncol 18:44-46, 1995.
62. Alvarez M, Wilson WH, Setser A, et al: Phase II study of EPOCH chemotherapy in previously untreated intermediate-grade (IG) non-Hodgkin's lymphomas (NHL). Blood 86(10) (Suppl 1): 1995 (abstract 1083).
63. The international Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 392:987-994, 1993.
64. Sparano JA, Wiernik PH, Strack M, et al: Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's lymphoma: A follow-up report of a highly active regimen.Leukemia Lymphoma 14:263-271, 1994.
65. Sparano JA, Wiernik PH, Leaf A, et al: Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: Evidence for a schedule-dependent effect favoring infusional administration of chemotherapy. J Clin Oncol 11:1071-1079, 1993.